A new imaging approach could change how doctors diagnose prostate cancer by helping nearly half of men avoid unnecessary biopsies while still reliably detecting serious cases. Researchers in Australia tested PSMA PET scanning, a technology traditionally used to track advanced prostate cancer, as an early detection tool for men with suspicious findings on MRI scans. The results suggest this strategy could reduce overdiagnosis of low-risk cancers while maintaining the ability to catch clinically significant disease .

What Is PSMA PET Imaging and How Does It Work?

PSMA PET (prostate-specific membrane antigen positron emission tomography) is an advanced imaging scan that detects a protein found on prostate cancer cells. Doctors have used it for years to stage advanced cancers and find recurrence after treatment. The PRIMARY2 trial, presented at the European Association of Urology conference in 2026, tested whether this technology could be moved earlier in the diagnostic process, before a biopsy is even performed .

The study involved men from seven Australian hospitals who had already undergone MRI scans showing less aggressive-looking lesions, classified as PI-RADS 2 or PI-RADS 3. These men were then randomized to either standard care (systematic biopsy) or PSMA PET scanning followed by targeted biopsy only if the scan showed suspicious findings. If the PSMA PET was negative, patients avoided a biopsy entirely .

What Did the Trial Actually Show?

The results addressed three critical questions that matter to patients: Can the test find aggressive cancers? Can it help men avoid unnecessary biopsies? And can it prevent overdiagnosis of low-risk disease?

• Biopsy Avoidance: Approximately 49% of men in the PSMA PET group were able to skip a biopsy entirely, reducing unnecessary procedures and their associated discomfort and risks.
• Clinically Significant Cancer Detection: The PSMA PET approach was non-inferior to standard biopsy in finding aggressive prostate cancers, meaning it did not miss serious cases that needed treatment.
• Overdiagnosis Reduction: PSMA PET reduced the rate of detecting insignificant prostate cancer, which refers to low-grade, low-volume disease unlikely to threaten a man's life but that still requires management once found.

These findings matter because prostate cancer diagnosis has long struggled with a fundamental tension: how to catch dangerous cancers without unnecessarily diagnosing slow-growing ones that may never cause harm. The PRIMARY2 trial suggests PSMA PET imaging could help resolve this dilemma .

How Might This Change Prostate Cancer Screening?

While the results are promising, experts emphasize this approach is not yet ready for immediate widespread use. The technology must go through regulatory approvals, insurance coverage decisions, and longer-term follow-up studies to confirm that men who avoided biopsies truly remained safe over many years. However, the pathway forward appears clear .

"This is a big study. Is it ready for prime time tomorrow? I think probably not. There's going to be additional validation following these patients a little bit longer, but we're certainly seeing that you don't want to miss significant prostate cancer and you don't want to over diagnose insignificant prostate cancer, and to hit both of those metrics," explained Dr. Zachary Klaassen, a urologist at Wellstar MCG Health.

Dr. Zachary Klaassen, Urologist at Wellstar MCG Health

The trial was funded by the Prostate Cancer Foundation and led by Dr. James Buteau, a PCF young investigator award recipient. This funding model highlights how research investment in both projects and emerging researchers can translate into clinical advances that change medical practice .

Where Does This Fit Into Current Prostate Cancer Screening Debates?

The prostate cancer screening landscape has been complicated for years. A comprehensive systematic review analyzing four major randomized trials and one cohort study found that PSA (prostate-specific antigen) blood testing was associated with approximately one fewer prostate cancer death per 1,000 men screened over 9.5 to 22 years, representing a 12% relative reduction in mortality. However, the same review noted that PSA screening also led to overdiagnosis in some trials, with estimates ranging from 2.3% to 10.3% of men receiving unnecessary diagnoses over 10 to 14 years .

The overall quality of evidence supporting PSA screening remains low, which is why researchers continue exploring better approaches. PSMA PET imaging represents one such innovation, potentially offering a more targeted way to identify men who truly need further evaluation while sparing others from unnecessary procedures .

Steps to Understanding Your Prostate Cancer Risk

• Know Your Risk Factors: Age, family history, and race are key factors that influence prostate cancer risk and screening recommendations. Men over 50, those with a family history of prostate cancer, and Black men should discuss screening options with their doctor.
• Discuss PSA Testing: Talk with your healthcare provider about whether PSA blood testing is appropriate for you, considering both potential benefits and harms including false positives and overdiagnosis.
• Ask About MRI and Advanced Imaging: If your doctor recommends further evaluation, ask whether MRI or newer imaging technologies like PSMA PET might be available to help guide next steps and potentially avoid unnecessary biopsies.
• Understand Biopsy Alternatives: As new technologies emerge, inquire whether targeted biopsy approaches or imaging-guided strategies might reduce your need for invasive procedures.

The PRIMARY2 trial represents an important step forward in making prostate cancer diagnosis more precise and less burdensome for patients. While PSMA PET imaging is not yet standard practice for initial diagnosis, the evidence suggests it could become part of the diagnostic toolkit within the next few years, pending regulatory approval and insurance coverage decisions. For men concerned about prostate cancer risk, the key takeaway is that screening and diagnostic approaches are evolving, and conversations with healthcare providers should focus on personalized risk assessment rather than one-size-fits-all recommendations .